Champions Oncology, Inc.CSBRNASDAQ
Loading
EV to Sales HistoryFair Value
Percentile Rank29
3Y CAGR-7.3%
5Y CAGR-9.4%
Studio
Year-over-Year Change

Enterprise value to sales ratio

3Y CAGR
-7.3%/yr
vs -2.7%/yr prior
5Y CAGR
-9.4%/yr
Consistent
Acceleration
-4.6pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive growthFair Value
PeriodValueYoY Change
20251.65+17.4%
20241.41+17.8%
20231.19-42.4%
20222.07-41.7%
20213.55+31.4%
20202.70-26.6%
20193.69+59.3%
20182.31+43.4%
20171.61-41.7%
20162.77-